Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Submitted by
admin
on October 5, 2013 - 9:31am
Source:
Yahoo/Globe Newswire
News Tags:
ofatumumab
GSK
Genmab
Arzerra
leukemia
chronic lymphocytic leukemia
Headline:
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Do Not Allow Advertisers to Use My Personal information
